Treatment-refractory cancers

Clinical trials for Treatment-refractory cancers explained in plain language.

Never miss a new study

Get alerted when new Treatment-refractory cancers trials appear

Sign up with your email to follow new studies for Treatment-refractory cancers, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

Immune cocktail shows promise in early trial for stubborn cancers

Disease control Completed

This early-phase study tested a new mix of three drugs—IL-15, nivolumab, and ipilimumab—in 31 adults with cancers that no longer respond to standard treatments. The goal was to find the safest dose and see if the combination could help the immune system attack tumors. Participant…

Matched conditions: TREATMENT-REFRACTORY CANCERS

Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jun 27, 2026 08:05 UTC

Treatment-refractory cancers

Get alerted when new Treatment-refractory cancers trials appear

Immune cocktail shows promise in early trial for stubborn cancers